These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 27537991

  • 1. IL-4 and IL-13 Inhibition in Atopic Dermatitis.
    Matsunaga MC, Yamauchi PS.
    J Drugs Dermatol; 2016 Aug 01; 15(8):925-9. PubMed ID: 27537991
    [Abstract] [Full Text] [Related]

  • 2. The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis.
    Silverberg JI, Kantor R.
    Dermatol Clin; 2017 Jul 01; 35(3):327-334. PubMed ID: 28577802
    [Abstract] [Full Text] [Related]

  • 3. Asthma and Atopic Dermatitis: A Review of Targeted Inhibition of Interleukin-4 and Interleukin-13 As Therapy for Atopic Disease.
    Buzney CD, Gottlieb AB, Rosmarin D.
    J Drugs Dermatol; 2016 Feb 01; 15(2):165-71. PubMed ID: 26885783
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dupilumab for Moderate-to-Severe Atopic Dermatitis.
    Vangipuram R, Tyring SK.
    Skin Therapy Lett; 2017 Nov 01; 22(6):1-4. PubMed ID: 29091379
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Biologics for Atopic Dermatitis.
    Boguniewicz M.
    Immunol Allergy Clin North Am; 2020 Nov 01; 40(4):593-607. PubMed ID: 33012322
    [Abstract] [Full Text] [Related]

  • 8. Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis.
    Pescitelli L, Rosi E, Ricceri F, Pimpinelli N, Prignano F.
    Curr Pharm Biotechnol; 2021 Nov 01; 22(1):73-84. PubMed ID: 32525769
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. IL-13 antagonists in the treatment of atopic dermatitis.
    Tubau C, Puig L.
    Immunotherapy; 2021 Mar 01; 13(4):327-344. PubMed ID: 33430628
    [Abstract] [Full Text] [Related]

  • 12. Drug evaluation review: dupilumab in atopic dermatitis.
    Hamilton JD, Ungar B, Guttman-Yassky E.
    Immunotherapy; 2015 Mar 01; 7(10):1043-58. PubMed ID: 26598956
    [Abstract] [Full Text] [Related]

  • 13. IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis.
    Morioka T, Yamanaka K, Mori H, Omoto Y, Tokime K, Kakeda M, Kurokawa I, Gabazza EC, Tsubura A, Yasutomi Y, Mizutani H.
    Br J Dermatol; 2009 Jun 01; 160(6):1172-9. PubMed ID: 19416272
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Therapeutic targeting of the IL-13 pathway in skin inflammation.
    Tubau C, Puig L.
    Expert Rev Clin Immunol; 2021 Jan 01; 17(1):15-25. PubMed ID: 33275064
    [Abstract] [Full Text] [Related]

  • 18. Dupilumab for the treatment of adolescents with atopic dermatitis.
    Senner S, Seegräber M, Frey S, Kendziora B, Eicher L, Wollenberg A.
    Expert Rev Clin Immunol; 2020 Jul 01; 16(7):641-650. PubMed ID: 32720530
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach.
    Di Lernia V.
    Expert Opin Ther Targets; 2015 Jan 01; 19(1):87-96. PubMed ID: 25283256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.